STUDY QUESTION: Which treatment-related factors are (dose-dependently) associated with abnormal hormonal and ultrasound markers of ovarian reserve in female childhood cancer survivors (CCSs)?
Introduction
Childhood cancer treatment may compromise ovarian function in female childhood cancer survivors (CCSs), leading to delayed or arrested puberty, infertility, subfertility and adverse pregnancy outcomes (Bath et al., 2002; Green et al., 2002 Green et al., , 2009b Thomson et al., 2002; Chemaitilly et al., 2006; Sudour et al., 2010; Barton et al., 2013; Thomas-Teinturier et al., 2015; Chow et al., 2016) . Moreover, treatment can induce premature menopause, since it may deplete the nonrenewable pool of primordial follicles in the ovary (Hamre et al., 2012; Nielsen et al., 2013) . The size of this pool is defined as ovarian reserve (Findlay et al., 2015) , whereas the term ovarian function is often used to describe a broader concept. This concept includes the various physiological mechanisms involved in the occurrence of an ovulating follicle each month and the production of reproductive hormones for additional future reproductive needs and more general health issues (Genazzani and Tarlatzis, 2016. Springer, Cham, Switzerland) . Knowing who is at risk of a decreased ovarian reserve, and thus, a shorter than anticipated reproductive window, is important to adequately counsel CCSs and future patients regarding family planning and fertility preservation.
Given the invasive nature of histological evaluations of ovarian tissue, the assessment of ovarian reserve has relied on indirect, surrogate markers. These include follicle stimulating hormone (FSH), antiMüllerian hormone (AMH), inhibin B and antral follicle count (AFC) (Lambalk, 2015) . Assessing more than one marker appears useful in delineating specific stages in the natural transition to menopause (Su et al., 2010) . Values of AMH and AFC have shown to decrease gradually with age, in contrast to FSH (the traditional marker of ovarian reserve), which starts to rise only when ovarian reserve is significantly reduced, leaving a limited reproductive window, if any. Currently, AMH and AFC are considered the most promising markers. They have shown to be significantly correlated with ovarian reserve, as assessed by manual counts of non-growing follicles in ovarian tissue samples (Hansen et al., 2011) .
Previous studies addressing ovarian function and ovarian reserve in female CCSs often lacked a full panel of clinical ovarian reserve tests. In addition, they often relied on self-reported data only, had incomplete follow-up, or lacked a (large) comparison group (Larsen et al., 2003a; Chemaitilly et al., 2006 Chemaitilly et al., , 2017 Lantinga et al., 2006; Sklar et al., 2006; Signorello et al., 2010; Barton et al., 2013) .
The current study aimed to identify treatment-related factors associated with a reduced ovarian reserve in a large cohort of female CCSs using, for the first time, an extensive set of clinical ovarian reserve markers. Moreover, associations between these markers were evaluated.
Materials and Methods

Study design and participants
The DCOG LATER-VEVO study is a Dutch nationwide retrospective cohort study evaluating fertility, ovarian reserve, and premature menopause among adult female 5-year CCSs. The study population consisted of CCSs from the DCOG-LATER cohort (n = 2237) and a comparison group including sisters of participating CCSs and women from the general population (GP controls). Eligibility criteria, detailed study characteristics and comparisons between both types of controls have been described previously (Overbeek et al., 2012; van den Berg et al., 2014) and are summarized below. The current manuscript focusses on the participants of the DCOG LATER-VEVO study for whom ovarian reserve markers have been assessed.
Cohort characteristics
Eligible cohort members were selected from a cohort of patients treated for childhood cancer between 1963 and 2002 at one of the seven Dutch paediatric oncology -and stem cell transplant centres, collectively known as the Dutch Childhood Oncology Group -Long Term Effects after Childhood Cancer (DCOG-LATER). This group has developed a nationwide electronic database including patient and treatment details of all childhood cancer survivors (CCSs) in the Netherlands (DCOG-LATER database).
The DCOG LATER cohort consists of those female CCSs who were treated for a malignancy or central nervous system tumour before the age of 18, who survived for at least 5 years after diagnosis, and who were at least 18 years at study entry (n = 2237 at database freezing date 1 January 2011) (Figure 1 ). We excluded 132 CCSs who fulfilled the exclusion criteria: those CCSs of whom contact details were unknown despite extensive tracing were considered lost to follow-up (n = 119). Of CCS who were deceased before the start of the study (n = 237) only treatment data and cause of death were abstracted. One CCS had died in the peri-partum period due to pulmonary embolism.
A total of 1749 female CCSs were eligible and thus invited for participation in the DCOG LATER-VEVO study. From the total eligible cohort 1106 (63%) consented to participate (classified as participants). Those who did not respond to the invitation (n = 272), those who indicated that they did not want to participate (n = 343), and those who had previously indicated that they were not willing to participate in research (n = 28) were classified as non-participants.
To determine the potential for introducing bias into the studied cohort, we compared demographic and cancer-related characteristics among participants, non-participants, those lost to follow-up and those deceased (Supplementary Table SI) . We found that the participants were similar to the non-participants with regard to age at study (or for those lost to follow-up, the age at which the cohort was assembled), age at diagnosis, and diagnosis. The type of treatment given differed between participants and non-participants. The non-participants did not differ from those lostto-follow up (data not shown). The deceased were more likely to have been diagnosed with CNS tumours and bone tumours, and were more likely to have been treated with chemotherapy and radiotherapy or radiotherapy alone.
Comparison group
To allow for comparisons with a population that had not been treated for cancer, two types of control groups were used: sisters of participating CCSs and controls from the general population.
Basic characteristics as well as several fertility-related characteristics were compared in both control groups and have been described in detail earlier (van den Berg et al., 2014) . The participation rate of sisters was much higher than control participants from the general population (74% versus 21%, respectively), although considerably more effort was involved in recruiting controls from the general population. Participants in this group were significantly older and more highly educated than sister controls (P < 0.001 for both groups). No significant differences were observed between both types of control groups in several fertility-related characteristics, suggesting minimal bias owing to selective participation. Figure 1 Flow chart of childhood cancer survivors (CCSs), sister controls and general population (GP) controls invited for the study.
Data collected for CCSs and controls were the same, with the exception of data related to the anti-cancer treatment in the past.
Data collection procedures
Data were collected by questionnaire, blood sampling and transvaginal ultrasound measurements of the ovaries. The questionnaire addressed socio-demographic characteristics, life-style behaviour, sexual activity status, parity, menstrual cycle characteristics, menopause and use of exogenous reproductive hormones. Menopausal women were defined as those women who reported not to have had any menses in the past 12 months (not due to pregnancy, breast feeding or use of contraceptives), as well as those who reported to use hormone replacement therapy (HRT) at time of study. Premature menopause was defined as a menopause before the age of 40 years.
Participant groups
CCSs as well as controls could consent to the questionnaire only or to the questionnaire combined with a clinical visit. Since data presented in the current manuscript mainly regards those women consenting to the clinical part, it is important to assess whether differences exist between the questionnaire-only-group and the clinical-group. With regard to possible selection bias, we evaluated the differences in characteristics between those participating in the questionnaire part only and those participating in both the questionnaire and the clinical part (blood and/or ultrasound) of the study.
When comparing CCSs consenting only to completing the questionnaire (CCS-Q) to those consenting to the questionnaire and the clinical part of the study (CCS-Cl), CCS-Cl were younger, less likely to have been pregnant, and less likely to have experienced menopause. However, BMI, level of education, smoking status and the proportion ever having had sexual intercourse were similar (data not shown).
CCS-Cl were also younger and less educated than controls participating in the questionnaire and the clinical visit (C-Cl). In addition, CCS-Cl were less likely to have been pregnant and more likely to have experienced menopause than C-Cl. C-Cl were comparable to controls only completing questionnaire data (C-Q) with regard to education, smoking, virginity rates, but were older, less likely to have been pregnant and less likely to have reached menopause (data not shown).
Women who provided both a blood sample and an ultrasound measurement were significantly older and had a higher level of education compared to those who provided a blood sample only. Among the controls, the proportion of women who had given birth was significantly higher in the blood+ultrasound group. Proportions of menopausal women did not differ significantly for CCS or controls. Finally, the proportions of women who never had sexual intercourse were significantly lower in the ultrasound groups, which is not surprising as women who reported never to have had sexual intercourse were primarily excluded from ultrasound measurements unless they actively stated that they were willing to undergo this examination for various reasons (data not shown).
Hormonal measurements
All laboratory analyses were performed by the endocrine laboratory of the VU University Medical Center Amsterdam. Serum FSH levels were analysed by an immunometric assay (Delfia, Perkin Elmer, Wallac, Turku, Finland), with a lower limit of quantitation (LLOQ) of 0.5 IU/l. The intraassay and inter-assay coefficient of variation (CV) were 5% and 7% respectively at a concentration of 2 IU/l, whereas these coefficients were 3% and 6% respectively at a concentration >4 IU/l. An ultra-sensitive immunoassay (pico-AMH, AnshLabs, USA) was used to measure serum AMH since we expected a significant number of the CCSs to have low AMH levels. The intra-assay CVs were 4.1%, 1.6%, 1.8%, and 2.8% as determined at concentrations of 29 pg/ml, 126 pg/ml, 304 pg/ml, and 656 pg/ml, respectively. Inter-assay CV was 2.5% at a level of 55 pg/ml. Inhibin B was measured in serum by the Gen II Inhibin B ELISA (Beckman Coulter). The LLOQ was 11 ng/l and the intra-assay and inter-assay CV were <9% and <10% at all concentrations, respectively.
Validation of the pico-AMH assay
Prior to the study the analytical performance of the pico-AMH assay was investigated by performing an extensive validation. For this purpose, serum samples were drawn from 80 subjects of whom it was expected AMH levels to vary broadly (i.e. 30 women with normal FSH levels (<10 U/l) and a regular menstrual cycle, 20 women with FSH levels between 10 and 20 U/l and a menstrual cycle, 10 women with polycystic ovary syndrome (PCOS), 10 menopausal women, and 10 men. Serum samples were stored at −20°C until analysis. All samples were diluted before being analysed with the pico-AMH assay according to the instructions of the manufacturer.
Results show that the intra-assay coefficients of variation (CV) as determined in serum specimens in duplicate at levels of 29 pg/ml, 126 pg/ml, 304 pg/ml and 656 pg/ml were 4.1%, 1.6%, 1.8% and 2.8% respectively. The inter-assay CV in a serum sample containing 55 pg/ml, was 2.5% (n = 7). Matrix interference was tested by comparing serum, heparin plasma and EDTA plasma, drawn at the same time in each of eight healthy subject subjects. Results in heparin plasma were 5% higher (P = 0.047) and in EDTA plasma were 4% higher (NS) compared to the paired serum samples. Samples could be diluted in a linear way (n = 3: R = 0.998, R = 0.999 and R = 0.997). Addition of AMH standard from the kit itself to serum samples led to a mean recovery of 90% (n = 4). Five serum samples underwent three freeze-thaw cycles but did not show a change compared to the result obtained upon thawing the first time (99%). We performed a comparison with the Gen II assay in 67 of the above described serum samples with a range from 2 to 15 000 pg/ml (Anshlabs assay). The comparison resulted in the following Passing & Bablok equation: AMH Gen II = 1.22 AMH Anshlabs + 74 (pg/ml) (Pearson correlation of R = 0.95). We did not specifically study the lower limit of quantitation (LLOQ), but given the observation that intra-assay CV at 29 pg/ml is only 4.1%, we submit that the LOQ of the Anshlabs AMH assay is about 10 times lower than the LOQ of the Gen II assay (200 pg/ml in our hands).
Outcome definition
Our primary outcome was ovarian reserve, evaluated by hormonal (FSH, AMH and inhibin B levels) and transvaginal ultrasound (number of antral follicles sized 2-10 mm in both ovaries) markers. Since both AMH and AFC gradually decline with increasing age (Nelson et al., 2011; Bozdag et al., 2016) , low AMH and low AFC were defined using age-specific cutoff values based on the included control population. Values were considered low when >2 SD below the mean of the corresponding age group of controls (see below). For defining high FSH and low inhibin B, fixed cutoff values were used (>10 U/l and <20 ng/l, respectively) since both markers remain relatively stable until a steep rise, respectively decline, in the last decade before menopause (Hall, 2015) .
All hormonal and ultrasound measurements were performed on cycle Day 2-5 of a natural menstrual cycle or randomly in case of amenorrhoea (no menses >6 months). Women on hormonal contraceptives (HCs) were asked to discontinue HC use at least 2 months prior to study measurements. Those not discontinuing HCs were measured on Day 7 of the HC-free week.
Calculation of age-specific cut-off values for defining low AMH and low AFC
The cut-off value to define low AMH and low AFC was calculated using the following procedure: first all control subjects of the study were sorted in ascending order based on age at study; all control subjects were then divided into subgroups of 30 subjects, starting with first 30 subjects (i.e. the youngest group), then on to the next 30 subjects, etc.; for each age subgroup the mean level of the concerning marker and the standard deviation (SD) were then calculated. Since median age at menopause is 52 years in the Western World, we excluded the 19 oldest participants (n = 10 controls and n = 9 CCSs).
Study participants were categorized as having low AMH and low AFC values if their outcome value was more than 2 SD below the mean of the corresponding age control subgroup. The age-specific cut-off values are listed per study outcome in Supplementary Table SII .
Ultrasound protocol
The measurements were performed using an ultrasound system with a transvaginal probe that can perform three-dimensional (3D) imaging. First, a 2D ultrasound assessment of the pelvis was performed after which an automated mechanical sweep produced the 3D data that were stored for later analysis. All 3D data were analysed by a single assessor using custom software (provided by Philips Ultrasound, Inc.) according to a pre-specified protocol. Antral follicle counts per ovary as well as the image quality of the ultrasound data were scored. The assessor analysing the 3D data had no knowledge of the previous childhood cancer diagnosis or treatment. If the ovary could not be found during the ultrasound evaluation, the antral follicle count for that ovary was imputed as zero for both 2D and 3D values.
Childhood cancer treatment
Details on prior cancer diagnosis and treatments (given for initial malignancy, recurrences, and any known new primary malignancies until time of study) were collected from original medical files. Cumulative doses of each chemotherapeutic (CT) agent and of radiotherapy (RT) administered to six body sites (cranium, spine, thorax, lower abdomen/pelvis, total body irradiation (TBI), other) were calculated for dose-effect analyses. Supplementary Tables SIII, SIV, and SV provide details on exposure to specific CT agents and RT body sites of the study cohort.
Statistical analyses
Overall effect of treatment was assessed by comparing all CCSs with controls using linear regression analyses; one for each log-transformed ovarian reserve outcome. Effects of specific treatments were assessed using three different regression models: model 1 included four broad treatment subgroups based on their presumed gonadotoxicity (Lee et al., 2006; van Dorp et al., 2016; Overbeek et al., 2017) , model 2a and 2b included accumulated scores for alkylating agent exposure (Alkylating Agent Dose (AAD) (Tucker et al., 1987; Green et al., 2009a) and Cyclophosphamide Equivalent Dose (CED) (Green et al., 2014) score), and model 3 included (doses of) individual CT agents and RT body sites. For the latter model all CT agents and RT body sites (given to ≥ 10 CCSs of whom blood and/or ultrasound data were available; see Table S1 ) with a P-value <0.20 in univariable analysis, were included in a multivariable model.
All model building procedures were based on linear regression analyses. Covariates were selected as follows. First, all individual CT agents and RT body sites used in ≥10 CCSs were dichotomized and analysed in separate univariable linear regression models. Four previously reported gonadotoxic alkylating agents given to <10 CCSs (busulfan, melphalan, chlorambucil and lomustine) were accounted for by adding a dichotomous variable 'Other gonadotoxic alkylating agents' to the regression model. All treatment variables with a P-value <0.20 in univariable analyses were included in a multivariable model. The final regression model was built using a stepwise backward elimination procedure (P < 0.05). For all CT agents and RT sites in the final model, dose-effect analyses were performed. Doses were categorized for each CT and RT dose variable separately using tertiles or, in case of low numbers, medians.
To facilitate clinical interpretation of data, logistic regression analyses were also performed for overall and specific effects of treatment using low AMH, low AFC, high FSH and low inhibin B values as dependent variables and using the same covariates as included in the corresponding linear regression models. All regression analyses were adjusted for attained age, time since diagnosis, pubertal status at treatment (i.e. menarche before/ during/after treatment), smoking status, body mass index and HC use at clinical measurement. Pairwise correlation coefficients between dichotomized treatment variables were above 0.8 for procarbazine/chlormethine and mercaptopurine/methotrexate only, indicating a general lack of colinearity. This is endorsed by the fact that no large regression coefficients (with opposite signs) nor inflated variance estimates were observed in any of the initial multivariable models.
Associations between markers were evaluated using AMH as 'reference marker'. Unlike AFC, AMH is not subject to inter-observer variation nor does it require invasive transvaginal ultrasound measurement (Iliodromiti et al., 2015) . In addition, in the current study AMH levels were determined in a larger group of participants compared to AFC measurements.
Analyses were performed using SPSS for Windows version 22.0 (SPSS, Chicago, IL).
Ethical approval
Approval was obtained from the relevant medical ethics committees and written informed was obtained consent from all participants.
Results
Of the 1749 CCSs and 1201 controls who received a study invitation, 1106 (63%) and 819 (68%), respectively, completed the questionnaire. Women who reported a current hormone-releasing intrauterine device (n = 52) or previous ovarian surgery (n = 35) or were aged ≥ 52 years (n = 19) were excluded from clinical assessments and included in the questionnaire only groups. Ultimately, blood samples were obtained from 564 CCSs and 390 controls, and of these, an additional ultrasound was performed in 458 CCSs and 342 controls (Figure 1) . Table I depicts demographic and treatment characteristics of all clinical study participants. Median (interquartile range (IQR)) age at the time of the study was significantly lower for CCSs than controls (26.9 (10.5) vs. 32.5 (12.0) years, respectively). Moreover, CCSs were significantly less likely to be highly educated. The clinical study measurements were performed during cycle Day 2-5 of a natural menstrual cycle for 69% of the CCSs and 70% of the controls, while 26% and 28%, respectively, were measured on Day 7 of the HC-free week. CCSs were significantly less likely to have had sexual intercourse and to have given birth at time of study, particularly in those aged >40 years. Moreover, significantly more CCSs had reached menopause (despite a younger average age at study) (5.7% of CCSs vs. 1.0% of controls) and had a non-surgically-induced premature (<40 years) menopause (4.1% for CCSs and 0% for controls, respectively (Tucker et al., 1987; Green et al., 2009a) ; cyclophosphamide equivalent dose (CED) score (Green et al., 2014) . e Postmenopausal women are defined as those women who have reported not to have had any menses in the past 12 months as well as those reported to use HRT at time of study invitation. f Surgically-induced menopause is defined as cessation of menses caused by bilateral oophorectomy.
(IQR) age at diagnosis and time since diagnosis was 5.8 (7.8) and 20.5 (10.9) years, respectively.
Overall effect of treatment
Median (IQR) AMH, AFC, FSH and inhibin B levels were similar in controls and CCSs: 2.1 (3.6) μg/l, 12.0 (13.0) follicles, 5.7 (2.9) U/l, and 68.0 (58.0) ng/l for CCSs and 1.9 (3.3) μg/l, 11.0 (11.0) follicles, 5.9 (2.7) U/l, and 73.0 (56.0) ng/l for controls, respectively. In both groups, AMH, AFC and inhibin B levels declined with increasing age, while FSH increased (Supplementary Figure SI) . Overall, linear regression analysis showed that, AMH, AFC, FSH and inhibin B levels did not differ significantly between CCSs and controls (data not shown). However, the overall proportion of women with low AMH and low AFC values was significantly higher for CCSs compared to controls (13.4% vs. 3.4% and 7.0% and 2.4%, respectively), whereas for FSH and inhibin B, the differences were not significant (12.1% vs. 10.1% and 17.7% vs. 13.6%, respectively) (Table II) . Moreover, stratified by age, the proportion of CCSs with abnormal ovarian reserve markers was significantly higher compared to controls in the two highest age groups (>35 years) for all markers except FSH. For AMH, borderline significant differences were also found in the younger age groups and for FSH, differences were seen in all but the highest age group. Multivariable logistic regression analyses showed that, overall, CCSs were at increased risk of low AMH and high FSH levels (OR 6.5 (95% CI, 1.3-32.5) and 14.3 (95% CI, 2.4-86.4), respectively), but not of low AFC and inhibin B levels (OR 4.7 (95% CI, 0.4-54.6) and 0.8 (95% CI, 0.3-2.5), respectively).
Effect of specific treatments
Combined treatment of alkylating CT and gonadotoxic RT (administered to 8% of CCSs) resulted in the lowest AMH, AFC, and inhibin B levels, and highest FSH levels in all age groups (Figure 2 ). Moreover, among CCSs aged 18-34 years, treated with alkylating CT and gonadotoxic RT, 46%, 19%, 27% and 43% had low AMH, low AFC, high FSH and low inhibin B levels, respectively. The proportions of similarly aged CCSs with abnormal ovarian reserve markers were at most 17% after alkylating CT only and 8% in those without any gonadotoxic treatment (Figure 2 ). The risk of having abnormal ovarian reserve markers was most markedly increased after treatment with lower abdominal/pelvic RT or TBI, with risk increasing further when combined with alkylating CT (Table III , Model 1). In these patients a significantly reduced ovarian reserve was illustrated by three out of four or by all markers, respectively. CCSs treated with alkylating CT without gonadotoxic RT also demonstrated signs of reduced ovarian reserve. However, this was less pronounced and illustrated by only two out of four markers. Model 2 shows that high AAD-scores were significantly associated with a reduced ovarian reserve according to all markers except AFC, whereas high CED-scores were significantly associated with low AMH and high FSH levels only. Finally, cyclophosphamide, procarbazine, a composite group of 'other alkylating agents' (i.e. busulfan, melphalan, chlorambucil or lomustine), mercaptopurine, dactinomycin, doxorubicin, mitoxantrone, spinal RT, abdominal/pelvic RT, TBI and the group of other RT were included in dose-effect analyses (Model 3) as these treatments were multivariably significantly associated with one or more abnormal ovarian reserve markers (Supplementary Table SVI 
<0.001
Age at study Values represent the number (%) of women. Differences between study groups were assessed using Pearson Chi-square tests. AFC, antral follicle count; AMH, anti-Müllerian hormone; CCSs, childhood cancer survivors; FSH, follicle stimulating hormone.
a Low AMH and low AFC were defined using age-specific cut-off values, i.e. 2 SD below the mean value of the control subjects within the concerning age group. High FSH and low inhibin B were defined using fixed cut-off values (i.e.
≥10 U/l and <20 ng/l, respectively). . Alkylating CT was defined as treatment with busulfan, carmustine, cyclophosphamide, chlorambucil, ifosfamide, lomustine, melphalan, procarbazine, temozolomide, chlormetine, ACNU or thiotepa. Low AMH and low AFC were defined using age-specific cut-off values, i.e. 2 SD below the mean value of the control subjects within the concerning age group. High FSH and low inhibin B were defined using fixed cut-off values (i.e. ≥10 U/L and <20 ng/l, respectively). 
Continued
Risk of low AMH and high FSH levels increased with increasing doses of procarbazine. For AFC and inhibin B, such clear doseeffect relationships were not found. Furthermore, higher doses of abdominal/pelvic RT resulted in increasing risks of low AFC and inhibin B levels, while this type of RT resulted in low AMH and high FSH levels, irrespective of dose. High-dose dactinomycin was significantly associated with low levels of AMH, while low and medium doses were not.
Associations between ovarian reserve markers
Pearson correlation coefficients between AMH-AFC, AMH-FSH, and AMH-inhibin B were r = 0.76, r = −0.52 and r = 0.63, respectively, for CCSs and r = 0.65, r= -0.46, and r = 0.50 for controls. When categorized by age, proportions of concordant combinations (i.e. low AMH with abnormal other marker) among CCSs were lowest in the youngest Other, Gy All analyses were adjusted for age at study, time since diagnosis, pubertal status at treatment, smoking status, current body mass index (BMI), and hormonal contraceptive use at time of clinical measurements. AFC, antral follicle count; AMH, anti-Müllerian hormone; CT, chemotherapy; FSH, follicle stimulating hormone; RT, radiotherapy; TBI, total body irradiation. a Low AMH and low AFC were defined using age-specific cut-off values, i.e. 2 SD below the mean value of the control subjects within the concerning age group. High FSH and low inhibin B were defined using fixed cut-off values (i.e. ≥10 U/l and <20 ng/l, respectively). b Not all numbers add up to the same total value due to missing data. c P-value trend: P-value for test of trend for total group of study participants (based on continuous dose variable). d Alkylating CT was defined as treatment with busulfan, carmustine, cyclophosphamide, chlorambucil, ifosfamide, lomustine, melphalan, procarbazine, temozolomide, chlormetine, ACNU or thiotepa. e The alkylating agent dose (AAD) score was calculated by adding the tertile score (1, 2 or 3) for each of the alkylating agents given to a particular CCS (Tucker et al., 1987; Green et al., 2009a) . The cyclophosphamide equivalent dose (CED) score was calculated using a specific equation (Green et al., 2014 ). An AAD-and CED-score of zero was assigned to both non-exposed CCSs and controls. Model 2a and 2b were additionally adjusted for RT abdomen/pelvis and TBI. f Model 3 includes those CT agents and RT sites that appeared to be significant in the multivariable regression model using dichotomous variables (ever vs. never treated). Non-exposed CCSs and controls were both assigned to the 'zero' or 'no' category of the CT agents and RT body sites. g Other gonadotoxic alkylating agents included busulfan (n = 2), melphalan (n = 7), chlorambucil (n = 2), lomustine (n = 3); total n = 14 pts. h None of the patients treated with low-dose, medium-dose, or high-dose mercaptopurine had low AFC values; none of the patients treated with low-dose mitoxantrone had high FSH values. i All patients treated with TBI had low AMH values.
age group for all three combinations (Supplementary Table SVII) . This trend was not observed among controls. Conversely, among CCSs with normal AMH levels, the proportions of concordant combinations (i.e. normal AMH with normal other marker) were lowest in the oldest age group for all three combinations, both in CCSs and controls.
Discussion
This is the first study to evaluate, on such a large scale, the long-term impact of childhood cancer treatment on both ultrasonographic and hormonal markers of ovarian reserve. Besides expanding previous knowledge on gonadotoxic therapies, concordances and discrepancies among markers of ovarian reserve were examined in the context of treatment-related ovarian damage. Although of great significance to those affected, the overall percentage of CCSs with abnormal markers appeared surprisingly low, even in those receiving presumed gonadotoxic chemotherapy only. Moreover, we showed that previously assumed gonadotoxic treatments (certain alkylating agents, lower abdominal radiotherapy and TBI) are indeed strongly associated with abnormalities in a panel of ovarian reserve markers. These and other novel findings are discussed in detail below. First, the proportion of CCSs with abnormal ovarian reserve markers was remarkably low, even after treatment with alkylating CT (6.5-13.0%). However, compared to controls, the proportions of CCSs with abnormal ovarian reserve markers increased more rapidly after age 35. This indicates that these women should be counselled to pursue pregnancy earlier as their reproductive lifespan may be shorter than anticipated. Moreover, specific groups of CCSs are at high risk of a decreased ovarian reserve, regardless of age. These CCSs should be counselled adequately and new patients receiving such treatments should be referred to a reproductive specialist for fertility preservation counselling.
Second, cyclophosphamide treatment appeared not to be associated with low AFC, high FSH, or low inhibin B levels. For AMH we did find such an association, although the ORs were low and no clear dose-effect relationship was found. Thomas-Teinturier et al. also found no association between cyclophosphamide treatment and several ovarian reserve markers (including AFC and FSH) (Thomas-Teinturier et al., 2015) . It should be noted, however, that the majority of the CCSs included in their study as well as in ours received <10 g/m 2 cyclophosphamide, consistent with contemporary treatment protocols. Future research should further investigate dose-effect relations of contemporary cyclophosphamide doses on ovarian function and ovarian reserve in CCSs. Third, the large sample size of our study enabled us to multivariably investigate the dose-related gonadotoxic effect of individual CT agents and RT body sites. To date, evidence on safe threshold doses of CT agents in particular has been lacking (Bath et al., 2002; van Dorp et al., 2016) . We were able to unambiguously establish the gonadotoxic effect of procarbazine, with a clear dose-effect relationship between increasing doses of procarbazine and increasing risks of low AMH and high FSH values. Moreover, we found that treatment with busulfan, melphalan, chlorambucil or lomustine also increased the risk of reduced ovarian reserve, although low numbers of CCSs treated with these agents compelled us to analyse these agents as one composite group of alkylating agents. Abdominal/pelvic RT affected all ovarian reserve markers at almost any dose, a finding consistent with previous studies (Larsen et al., 2003b; Chemaitilly et al., 2017) , and a clear dose-effect relationship was established for AFC and inhibin B. These evident dose-effect results are important for the design of future childhood oncology protocols in which the curative effect of the treatment is balanced with the risk of gonadotoxicity. Moreover, they can inform guidelines regarding surveillance of late effects for CCSs (Metzger et al., 2013; van Dorp et al., 2016) .
Finally, we found several discordances between combinations of ovarian reserve markers. Lack of a gold standard for ovarian reserve assessment prevented us from calculating performance measures such as sensitivity and specificity. Instead, reciprocal relationships between AMH and the other three markers were investigated. In many CCSs low AMH levels were not associated with abnormal AFC, FSH or inhibin B values, particularly in the younger age groups. This suggests that AMH starts to decline early in the sequence of events leading to menopause, long before changes in other markers occur.
This study has some unique assets compared to the previous studies on ovarian function and ovarian reserve in CCSs. First, we invited a well-defined nationwide cohort with long-term follow-up data. This benefits the generalizability and external validity of the study. Moreover, the number of CCSs and control subjects evaluated by transvaginal ultrasound and hormonal assessments is unprecedented. This allowed us to, besides evaluating the effects of individual types of treatment and dose-effect relationships, calculate age-specific cut-off values of AMH and AFC and compare these with values of CCSs. This seems more appropriate than using one fixed cut-off value for all ages as it may facilitate a more timely detection of a reduced ovarian function. Furthermore, AFC was evaluated by a single assessor, thereby eliminating inter-observer error, and an ultra-sensitive AMH immunoassay was used allowing accurate AMH measurements even in the lowest ranges. Additionally, all clinical measurements were carefully timed based on the participant's menstrual cycle pattern or HC use. Although AMH and AFC might be slightly underestimated and FSH overestimated in those measured on Day 7 of the HC-free week (van den Berg et al., 2010) , the impact on current study results will be limited since the proportions of CCSs and controls measured on HC7 were similar. Finally, besides hormonal and ultrasound measurements, we also measured clinically relevant outcomes such as self-reported menopause. Overall, 4% of the clinically measured CCSs in our study reported to have a non-surgical premature menopause. This point prevalence rate is somewhat lower compared to the prevalence mentioned by Chemaitilly et al. (11%) (Chemaitilly et al., 2017) . The fact that our study used a different definition of amenorrhoea (no menses for 12 months in our study versus 6 months in the other study) in combination with a larger proportion of women younger than 40 years in our study may explain this discrepancy. Women younger than 40 years at time of study are still at risk of a premature menopause in the future. As a consequence, we expect the percentage of premature menopause to increase with longer follow-up.
There are also some limitations. First, despite the large scale of the study, dose-effect relationships could not be investigated for all types of treatment due to a limited numbers of participants for specific analyses. Second, the proportion of parous women was lower among clinical participants compared to questionnaire-only participants, suggesting our study has been subject to some degree of participation bias (i.e. women who have greater concerns regarding their reproductive potential and/or those who have not yet made decisions regarding reproduction were more inclined to participate in the clinical part). This may have limited the generalizability of study results and could possibly have resulted in an overestimation of the prevalence of an impaired ovarian function or ovarian reserve. However, our results concerning differences between CCSs and controls can most probably be validly interpreted, since this trend was present in both groups. Third, although the analyses included a large number of comparisons, thereby increasing the likelihood of false positive results, we did not apply a correction for multiple testing. Our conclusions are based on trends and patterns across the different markers of ovarian reserve rather than individual significant results, and, inevitably, multiple comparison corrections increase the probability of producing false negative results and loss of statistical power. Finally, due to the cross-sectional design of our study, we were unable to evaluate the value of the ovarian reserve markers in predicting clinically relevant outcomes such as pregnancies or (premature) menopause.
In conclusion, although abnormal ovarian reserve markers are more frequently seen in CCSs compared to controls, the markers appear to be unaffected by cancer treatment in the majority of CCSs. However, the proportion of CCSs with abnormal markers increases significantly above the age of 35 years, implying that although ovarian function appears intact long after childhood cancer treatment, CCSs remain at risk of a reduced reproductive life span. Moreover, specific groups of CCSs and future patients are at high risk of a reduced ovarian function. They should be counselled accordingly about fertility preservation options, also after treatment, and referred to a reproductive specialist in a timely manner. Finally, future prospective studies among CCSs should focus on the impact of newly-developed treatment regimens on ovarian function and on the value of each of the ovarian reserve markers (measured both in the presence or absence of HC use) to predict a future pregnancy or premature menopause taking into account a possible role for genetic factors (van Dorp et al., 2013) . In the meantime, no recommendations can be made as to which of the ovarian reserve markers should be the marker of choice when it comes to counselling CCSs concerning their reproductive potential, as the actual clinical value of each of these markers remains to be established.
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